Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (9) ·
Adderall, Adderall XR, Mydayis (1) ·
Captagon (1) ·
Clozaril (1) ·
Dalmane (1) ·
Desoxyn (1) ·
Dexedrine (1) ·
Doral (1) ·
Fanapt (1) ·
Focalin, Focalin XR (1) ·
Geodon (1) ·
Halcion (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Lexotan (1) ·
Librium (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Mogadon (1) ·
Navane (1) ·
Onfi (1) ·
Orap (1) ·
Prolixin (1) ·
ProSom (1) ·
Restoril (1) ·
Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) ·
Rohypnol (1) ·
Saphris (1) ·
Serax (1) ·
Stelazine (1) ·
Thorazine (1) ·
Tranxene (1) ·
Trilafon (1) ·
Versed (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Monoamine releasing agent (1) ·
Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Phenothiazine D2 antagonist (4) ·
Prodrug of amphetamine + theophylline (1) ·
TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) ·
Thioxanthene D2 antagonist (1)
uses:
None (40) ·
ADHD, narcolepsy (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) ·
'"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)
starting dose:
preparations:
None (42) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
Desoxyn 5 mg tabs (1) ·
IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (40) ·
Category C (2) ·
Category C (per Desoxyn label) (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)
legal:
Showing below up to 45 results in range #1 to #45.